Table 5 Scenario analysis results
Results for carbapenem-sparing scenario where non-carbapenem drugs are given precedence | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
 Total costs per patient (USD 2015) | $36,416 | $36,038 | $378 |
 Total QALYs (discounted) per patient | 9.19 | 9.13 | 0.06 |
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) |  |  | $6020 |
Results using only nosocomial isolates | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
 Total costs per patient (USD 2015) | $42,737 | $42,358 | $378 |
 Total QALYs (discounted) per patient | 12.37 | 12.27 | 0.10 |
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | - | - | $3825 |
Results for high risk patients (aged 65Â years, requiring an ICU stay or catheter-associate infection) using nosocomial isolates | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
 Total costs per patient (USD 2015) | $37,947 | $37,557 | $390 |
 Total QALYs (discounted) per patient | 10.10 | 10.03 | 0.07 |
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | - | - | $6037 |
Results when lifetime health care expenditure for health survivors is excluded | Ceftolozane/tazobactam | Piperacillin/tazobactam | Incremental Ceftolozane/tazobactam - Piperacillin/tazobactam |
 Total costs per patient (USD 2015) | $7762 | $7583 | $179 |
 Total QALYs (discounted) per patient | 9.19 | 9.13 | 0.06 |
 Incremental Cost Effectiveness Ratio (Cost per discounted QALY gained) | - | - | $2842 |